349 related articles for article (PubMed ID: 34204242)
1. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Moon H; Ro SW
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204242
[TBL] [Abstract][Full Text] [Related]
2. Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma.
Moon H; Ro SW
J Liver Cancer; 2021 Mar; 21(1):1-11. PubMed ID: 37384270
[TBL] [Abstract][Full Text] [Related]
3. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Delire B; Stärkel P
Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway.
Wang W; Xiao Y; Li S; Zhu X; Meng L; Song C; Yu C; Jiang N; Liu Y
Am J Transl Res; 2019; 11(6):3816-3824. PubMed ID: 31312391
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.
Yang S; Liu G
Oncol Lett; 2017 Mar; 13(3):1041-1047. PubMed ID: 28454211
[TBL] [Abstract][Full Text] [Related]
6. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein kinases in hepatocellular carcinoma development.
Min L; He B; Hui L
Semin Cancer Biol; 2011 Feb; 21(1):10-20. PubMed ID: 20969960
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.
Bang J; Jun M; Lee S; Moon H; Ro SW
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631344
[TBL] [Abstract][Full Text] [Related]
9. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.
Ito Y; Sasaki Y; Horimoto M; Wada S; Tanaka Y; Kasahara A; Ueki T; Hirano T; Yamamoto H; Fujimoto J; Okamoto E; Hayashi N; Hori M
Hepatology; 1998 Apr; 27(4):951-8. PubMed ID: 9537433
[TBL] [Abstract][Full Text] [Related]
10. Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma.
Walker EJ; Rosenberg SA; Wands JR; Kim M
For Immunopathol Dis Therap; 2011; 2(2):195-204. PubMed ID: 21984963
[TBL] [Abstract][Full Text] [Related]
11. LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway.
Zhang Q; Cheng S; Cao L; Yang J; Wang Y; Chen Y
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32077915
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
13. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
Dimri M; Satyanarayana A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093152
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
15. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
16. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
17. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
18. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.
Li L; Zhao GD; Shi Z; Qi LL; Zhou LY; Fu ZX
Oncol Lett; 2016 Nov; 12(5):3045-3050. PubMed ID: 27899961
[TBL] [Abstract][Full Text] [Related]
19. Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies.
Gnoni A; Licchetta A; Memeo R; Argentiero A; Solimando AG; Longo V; Delcuratolo S; Brunetti O
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31766556
[TBL] [Abstract][Full Text] [Related]
20. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma.
Akula SM; Abrams SL; Steelman LS; Emma MR; Augello G; Cusimano A; Azzolina A; Montalto G; Cervello M; McCubrey JA
Expert Opin Ther Targets; 2019 Nov; 23(11):915-929. PubMed ID: 31657972
[No Abstract] [Full Text] [Related]
[Next] [New Search]
